Sanofi discontinues its Phase 3 MOBILIZE study of riliprubart in refractory CIDP after failing to show efficacy. The setback raises major doubts for Dianthus’ claseprubart (C1s inhibitor).
Cellectis got FDA RMAT for lasme-cel, an off-the-shelf CAR-T therapy for hard-to-treat leukemia that may speed up patient access.
Perrigo CEO resigned over conduct issues; interim CEO Albert Manzone appointed; company keeps 2026 sales and earnings targets unchanged.
Alterity’s drug ATH434 slowed MSA progression in trials, and FDA-approved Phase 3 plans bring it closer to becoming the first real treatment.
Novanta to buy Riverpoint Medical for up to $1.45B, doubling its recurring medical consumables revenue and expanding into minimally invasive surgical devices. Deal expected to close Q3 2026.
The deal gives GSK two potential best-in-class lung cancer drugs and accelerates its oncology growth.
